Racura Oncology Secures Governance Approval For Phase One Trial Testing Its Proprietary Formulation For Non-Small Cell Lung Cancer Treatment

MT Newswires Live

Mar 16

Racura Oncology (ASX:RAC) received governance approval from Monash Health for its phase one clinical trial assessing the safety, tolerability, and pharmacokinetics of RC220, its proprietary formulation of bisantrene, in combination with osimertinib, in patients with non-small cell lung cancer who have activating epidermal growth factor receptor mutations, according to a Monday Australian bourse filing.

Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations, the company said in an earlier filing.

Teams from Racura Oncology, Monash Health, and Contract Research Organisation Beyond Drug Development will meet at Monash Medical Centre in Clayton, Victoria, for site initiation and training on March 23. This will allow the first patients to be recruited into the trial.

The secondary and exploratory endpoints include progression-free survival, overall survival, changes in levels of circulating tumor DNA, and changes in the cancer-specific mutations present in patients.

Its shares were up 2% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2619190482"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619190482\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619190482?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619190482","market":"nz","top_or_hot":-1,"title":"Racura Oncology Secures Governance Approval For Phase One Trial Testing Its Proprietary Formulation For Non-Small Cell Lung Cancer Treatment","media":"MT Newswires Live","content":"<html><body><p> Racura Oncology (ASX:RAC) received governance approval from Monash Health for its phase one clinical trial assessing the safety, tolerability, and pharmacokinetics of RC220, its proprietary formulation of bisantrene, in combination with osimertinib, in patients with non-small cell lung cancer who have activating epidermal growth factor receptor mutations, according to a Monday Australian bourse filing.</p><p>Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations, the company said in an earlier filing.</p><p>Teams from Racura Oncology, Monash Health, and Contract Research Organisation Beyond Drug Development will meet at Monash Medical Centre in Clayton, <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>, for site initiation and training on March 23. This will allow the first patients to be recruited into the trial.</p><p>The secondary and exploratory endpoints include progression-free survival, overall survival, changes in levels of circulating tumor DNA, and changes in the cancer-specific mutations present in patients.</p><p>Its shares were up 2% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Racura Oncology Secures Governance Approval For Phase One Trial Testing Its Proprietary Formulation For Non-Small Cell Lung Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRacura Oncology Secures Governance Approval For Phase One Trial Testing Its Proprietary Formulation For Non-Small Cell Lung Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-16 09:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Racura Oncology (ASX:RAC) received governance approval from Monash Health for its phase one clinical trial assessing the safety, tolerability, and pharmacokinetics of RC220, its proprietary formulation of bisantrene, in combination with osimertinib, in patients with non-small cell lung cancer who have activating epidermal growth factor receptor mutations, according to a Monday Australian bourse filing.</p><p>Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations, the company said in an earlier filing.</p><p>Teams from Racura Oncology, Monash Health, and Contract Research Organisation Beyond Drug Development will meet at Monash Medical Centre in Clayton, <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>, for site initiation and training on March 23. This will allow the first patients to be recruited into the trial.</p><p>The secondary and exploratory endpoints include progression-free survival, overall survival, changes in levels of circulating tumor DNA, and changes in the cancer-specific mutations present in patients.</p><p>Its shares were up 2% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2619190482","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619190482","pubTimestamp":1773624182,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Racura Oncology  received governance approval from Monash Health for its phase one clinical trial assessing the safety, tolerability, and pharmacokinetics of RC220, its proprietary formulation of bisantrene, in combination with osimertinib, in patients with non-small cell lung cancer who have activating epidermal growth factor receptor mutations, according to a Monday Australian bourse filing.Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations, the company said in an earlier filing.Teams from Racura Oncology, Monash Health, and Contract Research Organisation Beyond Drug Development will meet at Monash Medical Centre in Clayton, Victoria, for site initiation and training on March 23. This will allow the first patients to be recruited into the trial.The secondary and exploratory endpoints include progression-free survival, overall survival, changes in levels of circulating tumor DNA, and changes in t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","RAC.AU":"RACE ONCOLOGY LTD"},"translate_title":"Racura Oncology获得治理批准，用于测试其用于非小细胞肺癌治疗的专有配方的一期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Racura Oncology (ASX:RAC) received governance approval from Monash Health for its phase one clinical trial assessing the safety, tolerability, and pharmacokinetics of RC220, its proprietary formulation of bisantrene, in combination with osimertinib, in patients with non-small cell lung cancer who have activating epidermal growth factor receptor mutations, according to a Monday Australian bourse filing.Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations, the company said in an earlier filing.Teams from Racura Oncology, Monash Health, and Contract Research Organisation Beyond Drug Development will meet at Monash Medical Centre in Clayton, Victoria, for site initiation and training on March 23. This will allow the first patients to be recruited into the trial.The secondary and exploratory endpoints include progression-free survival, overall survival, changes in levels of circulating tumor DNA, and changes in the cancer-specific mutations present in patients.Its shares were up 2% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}